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Abstract: The last decade has seen an extraordinary amount of effort devoted in biomedical research to the field of 
biomarkers. There have been some notable successes with novel markers being adopted into clinical practice bringing 
clear clinical benefit to some patients — particularly with the increasing numbers of medicines being approved with 
companion diagnostics. However, it is fair to say that there has not yet been the numbers of clinically valuable bio-
markers brought to medical practice that the research effort would seem to warrant. This paper evaluates examples of 
successful biomarkers, markers which might be considered partial successes and a few problematic examples and ar-
gues that more effort spent in the validation phase of marker development, and less in the discovery phase might be a 
more efficient way to allocate research resources. 
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Introduction 
oday, research into the use of biomarkers to 
discover, develop and rationally prescribe me-
dicines is dynamic and productive. The Food 
and Drug Administration (FDA) website lists 14 dif-
ferent biomarkers (analytes) which can be used as 
“companion diagnostics” to identify patients for 
treatment with 16 different therapeutics[1]. The science 
of companion diagnostics can be very refined so that 
some biomarkers, for example mutations within a par-
ticular gene, can be subdivided associating specific 
therapeutics with individual single nucleotide varia-
tions and different therapeutics with other mutations 
in that same gene (e.g. the T790M mutation within the 
EGFR gene indicates therapy with osimertinib, but 
safety and efficacy for that drug has not yet been es-
tablished for other mutations: e.g. G719X, exon 19 
deletions, L858R, exon 20 insertions, S768I, and 
L861Q — mutations for which other EGFR  
inhibitors are indicated). More generally in the USA, 
137 different medicines have pharmacogenomics 
biomarker information included in the drug label text, 
many with more than one associated marker[2]; these 
markers enable the better use of the medicines pro-
viding information on: drug exposure and clinical re-
sponse variability, risk for adverse events, geno-
type-specific dosing, mechanisms of drug action, and 
polymorphic drug target and disposition genes. It is 
estimated that perhaps three quarters of the drugs in 
clinical development in the major pharmaceuticals 
companies utilise biomarkers in their clinical studies.  
However, the broader field of biomarker discovery 
and development to create novel tools for identifying 
and characterising patients, e.g. tools for screening, 
diagnosis, prognosis, prediction, and assessment of 
disease activity[3], clearly lags far behind the increa-
singly successful efforts to marry biomarkers with 
drugs. This is not to dispute the tremendous utility of 
currently available and medically very important bio-
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markers (e.g. troponins in the diagnosis of myocardial 
infarction, d-dimers in the exclusion of deep venous 
thrombosis, and dozens of other markers in routine 
clinical use) but rather it is to recognise that the great 
efforts being made in biomarker discovery are not yet 
translating into commensurate numbers of biomarkers 
which have been adopted into widespread clinical 
practice. 
At the end of 2015, a search of the PubMed data-
base using the term “biomarker” revealed the startling 
figure of 753,760 publications in this database, of 
which 83,523 were review articles. Searches on the 
terms “precision medicine” identified 17,800 publica-
tions and “personalized medicine” 26,032. Figure 1 
shows the extraordinary growth in the numbers of 
publications — with more than 50,000 new articles 
being published per year in the recent period.  
It has been estimated that at least 100,000 different 
“biomarkers” have been described but the number of 
biomarkers applied in clinical practice is perhaps only 
around 100. What is the explanation for this disparity? 
The remainder of this article will consider lessons 
which can be learned from recent successfully devel-
oped biomarkers and from recent problematic results. 
It will be argued that diverting some research re-
sources away from biomarker discovery to more ri-
gorous and disciplined validation efforts for those few 
biomarkers which show strong associations with spe-
cific clinical conditions or outcomes might be ulti-
mately a more effective overall strategy for the field. 
It will also be argued that the path from discovering a 
biomarker to eventual clinical utility will be smoother 
and more efficient if coordinated efforts across differ-
ent research groups are made using a single reliable 
and reproducible technical platform so that results can 
easily be compared across studies. Perhaps less dis-
covery science and more pragmatic development ef-
fort is needed. 
 
 
 
Figure 1. This is a plot the numbers of publications registered 
each year in PubMed identified using the search term “bio-
marker’. There does seem to have been acceleration in the an-
nual numbers since the middle part of the last decade. More 
than 50,000 papers are now being published each year featuring 
biomarkers. 
Recent Successes 
It is important to recognise that there have been key 
advances in the last few years, especially in the on-
cology therapeutic area, despite the pessimism ex-
pressed as recently as 2010[4] and the genuine chal-
lenges involved[5]. This recent progress is also begin-
ning to spread more broadly into other therapeutic 
areas. 
One very good example is the increasing adoption 
of gene expression profiles in oncology for prognosis 
and to some extent for treatment guidance. Such pro-
files (or signatures) are used to identify patients with a 
high risk of early progression who require aggressive 
therapy (and conversely to identify low-risk patients 
who do not need this therapy and for whom avoiding 
the side effects of aggressive therapy is important). 
Commercially available tests include the gene signa-
tures of MammaPrintTM and ProsignaTM in breast 
cancer, the Oncotype DxTM tests (breast, prostate and 
colorectal) and the ProlarisTM prostate cancer test. 
Each signature comprises the expression profiles of 
between 20 and 70 genes. The key aspect is the exten-
sive and intensive development programmes[6−9] which 
have been undertaken for these assays. After thorough 
evaluation of the analytical validity of the signatures, 
they have been subject to careful clinical validation 
involving hundreds of patient samples from multiple 
collections, and have been shown to affect treatment 
decisions for patients in beneficial ways (Table 1).  
The development programmes for these biomarkers 
have been as much as a decade long in order to gener-
ate the data required for the assays to be incorporated 
into treatment guidelines[15] and to gain reimburse-
ment[16]. From a purely scientific perspective there are 
some interesting observations about these expression 
profiles: firstly, although the intended clinical uses for 
some of the above tests seem quite similar and the 
gene signatures seem to have been identified in similar 
ways, the actual lists of genes included in the signa-
tures show relatively little overlap (although maybe 
represent similar overall pathways) and the tests use 
rather different technical platforms (RT-PCR, micro-
array, NanoString)[17]; secondly, the tests do not al-
ways identify exactly the same patients for classifica-
tion as low or high risk for disease recurrence[18,19]. 
This could suggest that the utility of the tools derives 
not from a deep scientific understanding of the ana-
lytes (the genes, their relative degrees of expression 
and the actions of their products) nor even from a com-
plete knowledge of the link between the underlying  
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Table 1. Concepts of biomarker validation 
Phase of biomarker 
research Purpose of phase Comments References 
Analytical Validation • Establish that the assay actually measures the intended 
analyte 
• Determine the accuracy and robustness of the assay 
• Precision (repeatability) 
• Trueness (bias) 
• Limit of Detection, limit of quantification 
• Analytical specificity, interference and 
carry-over 
[10] 
Clinical Validation • Sensitivity and specificity of the assay — clinical accuracy 
(in the intended patient population) 
• Assay failure rates (and reasons) 
• Assay “no-call” rates, i.e., indeterminate results 
• Use blinded, retrospective analyses of 
prospectively collated samples with 
known outcomes 
• Evaluate assay performances in different 
labs and in different patient populations 
[11–13] 
Clinical Utility • Does the assay provide medically useful information which 
improves patient outcomes or reduces health-care costs? 
• Use prospective randomised clinical 
studies to show the assay improves out-
comes 
[11,14] 
 
molecular pathology and the patient’s eventual clinical 
outcome, but rather from the thorough, pragmatic and 
methodical development programmes pursued by the 
originators of these tools. 
Another interesting observation about these expres-
sion profiles is that they all had large effect sizes when 
first discovered (i.e. when a sample was positive for 
the assay that patient had a much increased chance of 
showing the relevant clinical outcome, i.e. early dis-
ease recurrence or specific histopathological subtype) 
and the probability that the signature was a chance 
observation was very low[20,21]. A review of multiple 
biomarkers across a broad range of indications sho-
wed that for many markers, the highly-cited paper 
which originally identified the marker often overesti-
mated the effect size in comparison with larger studies 
and in comparison with subsequent meta-analyses[22]. 
One interpretation of these findings might be that only 
biomarkers originally identified with large effect sizes 
subsequently survive further validation studies. 
In the cardiovascular field amongst many important 
traditional biomarkers, brain (derived) natriuretic pro-
tein (BNP) and N-terminal proBNP (NT-proBNP) have 
recently proven to be very useful markers to diagnose 
or exclude cardiac failure in acutely dyspnoeic pa-
tients, to provide some prognostic information in car-
diac disease and to distinguish between cardiac and 
pulmonary disease[23]. For these markers to have be-
come part of clinical practice, it has taken almost thir-
ty years of effort (BNP was first identified in 1988 and 
the related ANP was identified even earlier). Clinical 
validation and clinical utility have been established by 
the study of several thousands of patients in multiple 
small and large studies. 
Development of natriuretic peptides as biomarkers 
has unfortunately been hampered by the use of differ-
ent assays with different performance characteristics. 
Development has also been difficult because the 
markers show many of the characteristics of typical 
serum biomarkers: normal physiological variation and 
strong influences of patient characteristics (e.g. the 
markers are lowered in obese individuals, but in-
creased with impaired renal function and by concomi-
tant diseases such as atrial fibrillation). The example 
of the natriuretic peptides illustrates perfectly the sub-
stantial effort required to clinically validate novel 
biomarkers but perhaps also suggests that the marker 
might have been developed more efficiently if a single 
optimised assay had been used across multiple centres 
and clinical studies. 
The therapeutic area of inflammatory diseases pro-
vides another example of a recent hard-won potential 
success. With so many new medicines for Rheumatoid 
Arthritis recently approved and in development, there 
has been a substantial effort to identify biomarkers 
which might identify patients who will respond to a 
specific medicine or mechanism. Despite the explo-
sion of knowledge around cytokines, other inflamma-
tory mediators and the roles of cell adhesion mole-
cules it has proven extremely tough to find any dis-
ease activity markers more informative than the tradi-
tional measure of C-reactive protein (CRP) and 
straightforward assessment of patient symptoms and 
signs. Similarly, predictive markers to identify poten-
tial responders or non-responders have not been 
forthcoming. However, recently a panel of 12 serum 
proteins together with an algorithm to interpret the 
results of measures in this panel (Vectra DATM) may 
have finally been shown to improve upon traditional 
measures[24]. Across a range of patient populations 
with Rheumatoid Arthritis this score correlates with 
traditional measures of disease activity, but most im-
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portantly changes in the score over as little as two 
weeks of therapy predicted future clinical responses 
(measured at 6 weeks) in one study. If this finding is 
real and repeatable, the biomarker could provide two 
significant benefits: firstly the ability to avoid long 
and expensive trials of therapy in patients who will 
not gain benefit from a new drug, and secondly to 
simplify and considerably shorten phase 2 exploratory 
clinical studies with new drugs. Convincing validation 
of this finding is awaited with great interest. 
Recent Partial Successes: Biomarker Qualifi-
cation Programmes 
The evidence that biomarker development can be very 
difficult was further illustrated by the FDA Biomarker 
Qualification Programme (for drug development)[25]. 
There have been 19 submissions to this programme 
since 2008 of which: 
1) 9 are for qualification of preclinical safety 
markers 
2) 3 are for measures of clinical response (FDG 
PET for tumour effects; tumour volume meas-
ures; and MRI cartilage thickness measures for 
arthritis) 
3) 6 are for prognostic markers (cerebrospinal 
fluid (CSF) markers for the progression of 
Alzheimer’s Disease, hippocampal volume for 
the same condition, dopamine transporter PET 
for Parkinson’s Disease, total kidney volume 
for autosomal polycystic kidney disease, fi-
brinogen levels for chronic obstructive airways 
disease (COPD), and chronic kidney disease 
marker 273 for diabetic nephropathy), and 
4) 1 marker is for patient adherence (breath 2 bu-
tanone). 
Six data packages are under review or have been 
approved; three for preclinical toxicology groups of 
markers, and three for optimising patient selection for 
clinical trials (for invasive aspergillosis, COPD and 
polycystic kidney disease). The clinical packages com-
prise a great deal of data but the “approvals” are for 
only very modest reductions in the numbers of pa-
tients required in phase 3 clinical studies. These exa-
mples perhaps again stress the need to focus on mark-
ers which provide large effect sizes (and therefore me-
rit the effort of their development and validation). 
Alzheimer’s Disease is a condition for which there 
has been an enormous multi-programmatic effort to 
identify prognostic and predictive biomarkers. This 
effort has been driven by the desire to prevent pro-
gression of the disease, perhaps prevent dementia ever 
developing and even perhaps to reverse the disease 
process. Governments, regulatory authorities, phar-
maceuticals industries, charities and academic re-
searchers have come together to deliver several major 
coordinated programmes to discover and qualify bio-
markers, e.g. ADNI (I & II) and AIBL[26−28]. These 
programmes have required the collection of multiple 
samples of blood and CSF over many years from co-
horts of normal individuals, individuals with early 
cognitive decline at risk for disease and patients with 
frank Alzheimer’s whilst monitoring the cognitive 
function of these individuals. Great efforts have been 
made to analyse the serum and CSF samples using 
standardised techniques from only a small number of 
laboratories. Hundreds of patients have also provided 
positron emission tomography (PET) and volumetric 
MRI scans and through these efforts specific protocols 
for imaging conduct and analysis have been developed 
and standardised. 
Amongst the many successes of these programmes 
has been agreement on biomarker driven diagnostic 
criteria for both full-blown Alzheimer’s Disease and 
for incipient disease on the basis of CSF analytes (A 
beta 42, phospho-tau, total tau), amyloid PET neu-
ro-imaging, specific cognitive deficits and APOE4 
genotype[29−32]. Amyloid binding PET ligands have 
been brought to the market as a way of excluding pa-
tients from the diagnosis of Alzheimer’s Disease and 
as a method of identifying patients for clinical trials of 
novel medicines intended to arrest the progression of 
Alzheimer’s Disease at an early (possibly even prec-
linical) stage. Assay kits have been developed for 
blood and CSF analytes — though it is fair to report 
that preanalytic quality control remains an issue as 
does “trueness” across the various kits — especially 
for blood tests. 
These biomarker programmes have been astoni-
shingly successful in characterising, and analytically 
and clinically validating, specific markers. On the 
other hand, despite the programmes having been un-
derway for more than a decade, the eventual clinical 
utility of the markers is still not clearly determined. 
Certainly while amyloid PET ligands can help exclude 
a diagnosis of Alzheimer’s Disease as the cause of 
dementia, their approval by regulators was not met by 
reimbursement. A major study is currently underway 
(the IDEAS study) to demonstrate the clinical utility 
of amyloid PET Imaging[33]. Of the other markers, 
APOE4 genotype (and other much rarer dominantly 
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inherited genotypes) potentially provide prognostic 
information about the age at which Alzheimer’s Dis-
ease might develop. However, there are no currently 
available interventions which have been shown to de-
lay or reverse progression of the disease. In this dis-
ease area, the biomarkers have, unusually, been de-
veloped in advance of therapies rather than vice versa 
for the examples given elsewhere in this article. 
Some Recent Problematic Results 
Brookes[5] provides a good theoretical description as 
to why it is so difficult to develop and validate bio-
markers and Diamandis[4] provides a series of exam-
ples of lessons that can be learned from high-profile 
failures of validation. Amongst the many important 
points made by these authors four issues stand out: 
1) Exaggeration of the effect size of a putative 
biomarker in early discovery studies 
i. often by poor selection of the control tissue 
(or patient) samples; for example, not truly 
matching for age, gender, and other diseases 
of the same tissue 
ii. sometimes through poor case selection; for 
example, using end-stage disease 
2) Failure to fully disclose the methodology and 
failure to replicate the result in at least one 
other laboratory early in the validation process  
3) Not having a clear plan for the “intended use” 
for the biomarker 
i. what decision is information from the bio-
marker intended to support? 
ii. not recognising the harm that can follow 
from an incorrect decision 
4) Failing to understand the importance disease 
prevalence plays in the usefulness of a screen-
ing test and so underestimating the difficulties 
caused by false positive results (to patients and 
to healthcare providers). 
To these issues it is also possible to add (at least) 
another two: 
• retrospectively attempting to analytically and 
clinically validate complicated biomarkers 
during the course of extensive clinical studies 
of novel drugs 
• developing assays for recently discovered 
analytes with complex and only partially un-
derstood function 
A very good example of the fifth issue concerns re-
cent efforts to develop drugs, typically biologics, as 
therapeutics for subsets of patients with asthma[34,35], 
patients whose asthma is thought to have a molecular 
pathology consistent with the mechanism of action of 
the novel therapeutic. 
Given the recent successes in developing targeted 
therapies in oncology, at least a few of which were 
found to be associated with predictive biomarkers 
during the course of their clinical development (eg 
gefitinib, crizotinib), it has been tempting for phar-
maceuticals companies to embark on large clinical 
development programmes incorporating inadequately 
characterised biomarkers in the expectation that asso-
ciations between the markers and response will 
emerge from those clinical studies. The thinking be-
hind the choice of these biomarkers is naturally related 
to the supposed mechanism of action of the novel tar-
geted therapeutic. 
However, it is important to recognise that retros-
pective identification of predictive biomarkers only 
really works when it is easy to identify patients who 
are experiencing a profound clinical response, not 
seen in other patients. The link between a biomarker 
being present in profound responders and not present 
in non-responders is usually very obvious, and qualit-
ative rather than quantitative (i.e. a mutation or trans-
location is present or it is not). Conversely, the biom-
arkers used in asthma studies described above (blood 
and sputum eosinophil levels, so-called TH2 gene ex-
pression profile signatures, levels of inflammatory 
mediators such as periostin) are quantitative and com-
plex, and derived from assays with limited analytical 
validation. Clinically meaningful cut-offs for positive, 
negative and intermediate results have not been fully 
established in prior extensive untreated population  
cohort studies. Similarly, responsive patients in asth-
ma studies are difficult to distinguish from less well 
responding patients — there is a certain level of pla-
cebo response and natural variation in disease severity 
over time. Therefore, making the link between re-
sponse and a biomarker level is inherently extremely 
difficult and mathematically complex, with neither 
measures of disease severity nor of the biomarker 
providing well-founded data. It remains conceivable 
that a meaningful biomarker (beyond blood eosinophil 
levels) linking efficacy to a given drug might emerge 
from these asthma studies which have already in-
cluded thousands of patients but this does not as yet 
seem to have been an efficient use of clinical research 
resources. 
A very good example of the sixth issue (incom-
pletely understood analytes) concerns attempts to de-
velop individual microRNAs or panels of these ana-
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lytes as biomarkers, for example in heart failure and 
other cardiovascular diseases[36−38]. MicroRNAs are 
small molecules which serve to regulate transcription, 
usually each microRNA of which more than 1000 
have been identified, regulates multiple genes. They 
have definite potential as biomarkers as they are found 
“stabilised” in circulating blood either in exosomes or 
bound to protective proteins. Their potential utility as 
biomarkers was recognised in the cardiac and oncolo-
gy therapeutic areas more than a decade ago; RT-PCR 
is a viable technology to measure these markers and 
next generation sequencing offers a more advanced 
potential platform. However, because the precise role 
of any given microRNA is incompletely understood 
(and often is only inferred rather than proven) it has 
been extremely difficult to decide which molecules 
provide the most relevant information in any given 
situation and replication of findings across laborato-
ries and across assay technologies remains problemat-
ic. This problem is exacerbated when searching for 
panels of microRNAs with the increased risks of false 
discovery. It is reassuring to note that the titles of two 
publications[36,37] end with a query, and there is also an 
observation in another report that it is not clear that a 
new panel of four microRNAs provides information 
beyond that already available from traditional symp-
toms, signs and currently available markers[38]. Bear-
ing in mind that it has taken almost three decades to 
validate natriuretic peptides in these same indications, 
it seems that microRNA research is still in its relative 
infancy. 
Discussion 
For biomarkers to be adopted into widespread clinical 
practice they need reliably to provide useful clinical 
information. But, showing that this is true for any 
given marker is much more difficult than many dis-
covery orientated scientists imagine. The first step for 
a biomarker is to show an association between the 
marker and a clinical condition. This step seems to get 
the scientific recognition and the highly-cited publica-
tions. Unfortunately, this is only the very first step. 
Years, sometimes decades, of subsequent work is then 
required: to establish an analytical platform that is 
reliable and robust; to confirm the finding of the asso-
ciation and to provide some kind of clinically mea-
ningful quantification or cut-offs; and to demonstrate 
that the new finding provides information not other-
wise readily available to the clinician and that the ad-
ditional information influences the healthcare and 
health outcome for the patient in a meaningful way. 
How can scientists be incentivised to conduct this 
validation work? Here are a few suggestions: 
1) Journals (editors and reviewers) should avoid 
publishing biomarker “discoveries” until the 
discovery has been replicated in at least one 
other laboratory 
i. perhaps academic laboratories could form 
collaborative groups to attempt replications 
of each other’s findings? 
2) Biomarker discoveries should always be ac-
companied with a full revelation of the details 
of the assay methodology and with the full raw 
data being made available 
i. a particular issue can be the details of any 
algorithms used to generate scores from 
panels of biomarkers, sometimes even the 
underlying computer code can be important 
for replication 
3) Journals should encourage the publication of 
validation studies, both analytical and clinical. 
Studies which fail to replicate previous reports 
should be recognised as being just as important 
as those which do replicate. Both kinds of re-
sults are vital to scientific progress and merit 
accompanying editorials in those journals. 
For efficient redirection of resources, perhaps vali-
dation, or early de-validation, deserves as much rec-
ognition as biomarker discovery in answering the 
question, “What makes a good biomarker?”  
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